Key insights
- Becton Dickinson EVP Michael Feld sold a small amount of stock under a pre-arranged plan. Argus lowered its price target on BDX, while maintaining a Buy rating. BD received regulatory approvals in the EU and US for new products and initiated a debt tender offer. Medical technology pricing remains flat. Overall, the news is slightly negative due to the price target cut and executive sale, but the regulatory approvals provide some offset.
Michael Feld, Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co. (NYSE:BDX), sold common stock totaling $11,243 on April 27, 2026, according to a recent SEC Form 4 filing.
The transaction involved the disposal of 74 shares of Becton Dickinson common stock at a price of $151.94 per share. This sale was executed under a Rule 10b5-1 trading plan, which Mr. Feld adopted on February 7, 2025.The stock currently trades at $150.22, near its 52-week low of $149.87, and according to InvestingPro analysis, appears undervalued relative to its Fair Value. The company, a prominent player in the Healthcare Equipment & Supplies industry with a $42.8 billion market cap, has raised its dividend for 55 consecutive years. InvestingPro offers 9 additional exclusive tips and comprehensive Pro Research Reports for deeper analysis.
Following this transaction, Mr. Feld directly holds 21,159 shares of Becton Dickinson common stock. The company reports earnings on May 7, 2026.
In other recent news, BD announced it has received CE Mark approval for its Liverty TIPS Stent Graft, allowing for commercialization across the European Union. This development targets complications from portal hypertension in patients with cirrhosis. Additionally, BD received 510(k) clearance from the U.S. Food and Drug Administration for its Surgiphor 1000mL antimicrobial irrigation system, designed for surgical procedures.
In financial updates, BD has commenced tender offers to purchase up to $1.6 billion of its outstanding debt securities across 15 different series, with the highest priority given to the 6.700% Senior Notes due 2026. Meanwhile, Argus has lowered its price target for BD shares from $230 to $180, citing market turbulence but maintaining a Buy rating. The research firm continues to support BD’s strategic focus on growth opportunities in the Medical and Interventional segments.
Raymond James reported that medical technology pricing, including BD’s sector, has remained flat in 2025, following a brief positive trend in previous years. These recent developments reflect BD’s ongoing efforts in product innovation and financial management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.